BidaskClub Upgrades Regeneron Pharmaceuticals, Inc. (REGN) to “Strong-Buy”

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a report issued on Saturday.

REGN has been the topic of a number of other research reports. BMO Capital Markets raised their price objective on shares of Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the stock a “hold” rating in a report on Monday, May 15th. Vetr downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $408.86 price objective on the stock. in a report on Monday, April 24th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 14th. Canaccord Genuity set a $484.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday. Finally, Cowen and Company reissued a “hold” rating and issued a $380.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, May 15th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $443.49.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ REGN) traded down 1.75% on Friday, reaching $517.33. 1,885,482 shares of the company’s stock were exchanged. The firm’s 50 day moving average price is $456.19 and its 200 day moving average price is $393.90. Regeneron Pharmaceuticals has a 52-week low of $325.35 and a 52-week high of $519.65. The company has a market cap of $54.62 billion, a PE ratio of 62.62 and a beta of 1.53. Regeneron Pharmaceuticals also saw unusually large options trading activity on Friday. Traders purchased 1,150 put options on the company. This is an increase of approximately 496% compared to the average volume of 193 put options.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.42. The company had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.30 billion. Regeneron Pharmaceuticals had a net margin of 19.34% and a return on equity of 22.99%. The firm’s revenue was up 9.8% compared to the same quarter last year. During the same quarter last year, the firm posted $2.57 earnings per share. On average, analysts expect that Regeneron Pharmaceuticals will post $12.67 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “BidaskClub Upgrades Regeneron Pharmaceuticals, Inc. (REGN) to “Strong-Buy”” was originally published by Mideast Time and is the property of of Mideast Time. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.mideasttime.com/bidaskclub-upgrades-regeneron-pharmaceuticals-inc-regn-to-strong-buy/1808233.html.

In other Regeneron Pharmaceuticals news, SVP Michael S. Aberman sold 2,269 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $532.42, for a total transaction of $1,208,060.98. Following the completion of the transaction, the senior vice president now directly owns 9,193 shares of the company’s stock, valued at $4,894,537.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael S. Brown sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, March 29th. The stock was sold at an average price of $400.00, for a total transaction of $400,000.00. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at $400,000. The disclosure for this sale can be found here. Insiders have sold 60,396 shares of company stock valued at $28,884,734 over the last ninety days. 10.40% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its position in Regeneron Pharmaceuticals by 3,331.5% in the first quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock valued at $2,381,971,000 after buying an additional 5,967,733 shares during the last quarter. Norges Bank bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $291,560,000. Janus Capital Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 58.5% in the first quarter. Janus Capital Management LLC now owns 1,317,162 shares of the biopharmaceutical company’s stock worth $510,406,000 after buying an additional 486,119 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Regeneron Pharmaceuticals by 7.9% in the first quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock worth $2,377,590,000 after buying an additional 446,850 shares in the last quarter. Finally, Clearbridge Investments LLC raised its stake in shares of Regeneron Pharmaceuticals by 55.2% in the first quarter. Clearbridge Investments LLC now owns 690,254 shares of the biopharmaceutical company’s stock worth $267,480,000 after buying an additional 245,531 shares in the last quarter. 67.23% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:REGN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.